BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $358.3 million versus the consensus estimate of $351.62 million.

GUIDANCE:

BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.48 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.